Skip to main content
SpringerLink
Log in

Beyond MVAC: New and Improved Chemotherapeutics

  • Chapter
  • First Online:
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1014 Accesses

Abstract

With the introduction of cisplatin based combination chemotherapy, survival for patients with advanced bladder cancer has doubled from approximately 3–6 months with supportive care alone to over one year. The lack of curative potential coupled with significant potential toxicity fueled the search for more efficacious and less toxic regimens. Although median survivals have marginally improved since the original reports on MVAC, this likely is a result of stage migration and better supportive care. However, several alternative regimens have shown promising activity with less toxicity and applicability to a broader population of patients. Significant steps have also been made in the last several years in understanding the pathobiology of bladder cancer. These advances have led to trials investigating a variety of cytotoxic agents and biologically targeted agents as monotherapy or in combination with chemotherapy in hopes of increasing response rate and overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.

    PubMed  Google Scholar 

  2. von der Maase H, Sengelov L, Roberts J460T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–4608.

    PubMed  Google Scholar 

  3. Loehrer PJ, Sr., Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–1073.

    PubMed  Google Scholar 

  4. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564–2569.

    CAS  PubMed  Google Scholar 

  5. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050–1055.

    CAS  PubMed  Google Scholar 

  6. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–3077.

    PubMed  Google Scholar 

  7. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638–2646.

    CAS  PubMed  Google Scholar 

  8. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100:1639–1645.

    CAS  PubMed  Google Scholar 

  9. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–54.

    CAS  PubMed  Google Scholar 

  10. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441–3445.

    CAS  PubMed  Google Scholar 

  11. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394–3398.

    CAS  PubMed  Google Scholar 

  12. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264–2270.

    CAS  PubMed  Google Scholar 

  13. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247–3255.

    CAS  PubMed  Google Scholar 

  14. Bellmunt J, von der Maase H, Mead G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I Vol 25, 2007;25:No. 18S (June 20 Supplement): LBA5030.

    Google Scholar 

  15. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990;322:1129–1138.

    CAS  PubMed  Google Scholar 

  16. Llado ABJ, Kaiser G, et al. A dose finding study of carboplatin with fixed doses of gemcitabine in "unfit" patients with advanced bladder cancer. Proc Am Soc Clin Oncol 2000;19:344a.

    Google Scholar 

  17. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000;59:24–27.

    CAS  PubMed  Google Scholar 

  18. Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 2001;12:947–952.

    CAS  PubMed  Google Scholar 

  19. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003;97:2180–2186.

    CAS  PubMed  Google Scholar 

  20. Meluch AA, Greco FA, Burris HA, 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018–3024.

    CAS  PubMed  Google Scholar 

  21. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993–2998.

    CAS  PubMed  Google Scholar 

  22. Parameswaran RFM, Ansari F, et al. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Am Soc Clin Oncol 2001;20:200a.

    Google Scholar 

  23. MacVicar G, Hussain M. Special Considerations on the Management of Elderly Bladder Cancer Patients. In: SP L, M S, C S, eds. Textbook of Bladder Cancer. London: T&F-Informa; 2006.

    Google Scholar 

  24. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998;34:1208–1212.

    CAS  PubMed  Google Scholar 

  25. Albers P, Siener R, Hartlein M, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 2002;25:47–52.

    CAS  PubMed  Google Scholar 

  26. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994;5:182–184.

    CAS  PubMed  Google Scholar 

  27. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589–593.

    CAS  PubMed  Google Scholar 

  28. Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997;20:519–521.

    CAS  PubMed  Google Scholar 

  29. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853–1857.

    CAS  PubMed  Google Scholar 

  30. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937–940.

    CAS  PubMed  Google Scholar 

  31. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94:1395–1401.

    CAS  PubMed  Google Scholar 

  32. Fechner G, Siener R, Reimann M, Kobalz L, Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 2006;60:27–31.

    CAS  PubMed  Google Scholar 

  33. Krege S, Rembrink V, Borgermann C, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 2001;165:67–71.

    CAS  PubMed  Google Scholar 

  34. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 1995;154:1719–1722.

    CAS  PubMed  Google Scholar 

  35. Pagliaro LC, Millikan RE, Tu SM, et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 2002;20:2965–2970.

    CAS  PubMed  Google Scholar 

  36. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061–1070.

    CAS  PubMed  Google Scholar 

  37. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72–84.

    CAS  Google Scholar 

  38. Blumenreich MS, Yagoda A, Natale RB, Watson RC. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 1982;50:435–438.

    CAS  PubMed  Google Scholar 

  39. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998;78:1342–1345.

    PubMed  Google Scholar 

  40. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325–2333.

    CAS  PubMed  Google Scholar 

  41. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997;272:2534–2541.

    CAS  PubMed  Google Scholar 

  42. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 2004;305:866–869.

    CAS  PubMed  Google Scholar 

  43. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015–2025.

    CAS  PubMed  Google Scholar 

  44. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429–1437.

    CAS  PubMed  Google Scholar 

  45. Dreicer R, Li S, Manola J, Haas N, Roth B, Wilding G. Phase II trial of epothilone B analogue BMS-247550 in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:Abstract 4543.

    Google Scholar 

  46. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999;35:512–520.

    CAS  PubMed  Google Scholar 

  47. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 2002;7:159–166.

    CAS  PubMed  Google Scholar 

  48. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998;53:908–915.

    CAS  PubMed  Google Scholar 

  49. Bellmunt J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). Sub-category: Bladder Cancer J Clin Oncol 2008;26:abstract 5028.

    Google Scholar 

  50. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086–1095.

    CAS  PubMed  Google Scholar 

  51. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013–1021.

    CAS  PubMed  Google Scholar 

  52. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125–141.

    PubMed  Google Scholar 

  53. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454–1457.

    CAS  PubMed  Google Scholar 

  54. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284:L187–196.

    CAS  PubMed  Google Scholar 

  55. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002;161:1647–1656.

    CAS  PubMed  Google Scholar 

  56. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002;94:929–933.

    CAS  PubMed  Google Scholar 

  57. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001;61:3882–3885.

    CAS  PubMed  Google Scholar 

  58. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–1324.

    CAS  PubMed  Google Scholar 

  59. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–7803.

    CAS  PubMed  Google Scholar 

  60. Turner AG. Methotrexate in advanced bladder cancer. Cancer Treat Rep 1981;65 Suppl 1:183–186.

    PubMed  Google Scholar 

  61. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW, Jr. Methotrexate: an active drug in bladder cancer. Cancer 1981;47:1246–1250.

    CAS  PubMed  Google Scholar 

  62. Oliver RT, England HR, Risdon RA, Blandy JP. Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma. J Urol 1984;131:483–485.

    CAS  PubMed  Google Scholar 

  63. Knight EW, Pagand M, Hahn RG, Horton J. Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder. Cancer Treat Rep 1983;67:514–515.

    CAS  PubMed  Google Scholar 

  64. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002;20:1361–1367.

    CAS  PubMed  Google Scholar 

  65. Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent--pemetrexed disodium. Cancer 2003;97:2056–2063.

    CAS  PubMed  Google Scholar 

  66. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 1998;18:3235–3239.

    CAS  PubMed  Google Scholar 

  67. von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006.

    Google Scholar 

  68. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003;3:11–19.

    PubMed  Google Scholar 

  69. Li S, Dreicer R, Roth B, Manoloa J, Cooney M, Wilding G. Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium (E4802): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007;25:abstract 5079.

    Google Scholar 

  70. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:3451–3457.

    CAS  PubMed  Google Scholar 

  71. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361–373.

    CAS  PubMed  Google Scholar 

  72. Schulz W. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;Mar 23; [Epub ahead of print].

    Google Scholar 

  73. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713–725.

    CAS  PubMed  Google Scholar 

  74. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.

    CAS  PubMed  Google Scholar 

  75. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.

    CAS  PubMed  Google Scholar 

  76. Chow NH, Liu HS, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997;17:1293–1296.

    CAS  PubMed  Google Scholar 

  77. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166–176.

    CAS  PubMed  Google Scholar 

  78. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366–368.

    CAS  PubMed  Google Scholar 

  79. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619–1625.

    CAS  PubMed  Google Scholar 

  80. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530–2537.

    CAS  PubMed  Google Scholar 

  81. Bue P, Wester K, Sjostrom A, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998;76:189–193.

    CAS  PubMed  Google Scholar 

  82. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46 Suppl:S85–104.

    PubMed  Google Scholar 

  83. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10:4874–4884.

    CAS  PubMed  Google Scholar 

  84. Petrylak D, Faulkner J, Van Veldhuizen P, Mansukhani M. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 2003;22:Abstract 1619.

    Google Scholar 

  85. Phillips G, Halabi S, Sanford D, et al. Phase II trial of cisplatin, fixed-dose gemcitabine and gefitinib for advanced transitional cell carninoma of the urothelial tract: Preliminary results from CALGB 90102. Journal of Clinical Oncology 2004;22:4540.

    Google Scholar 

  86. Philips G, Sanford B, Halabi S, Bajorin D, Small EJ. Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102. J Clin Oncol 2006;24:abstract 4578.

    Google Scholar 

  87. Wülfing C, Machiels J, Richel D, Grimm M. A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. J Clin Oncol 2005;23:Abstract 4594.

    Google Scholar 

  88. Jimenez RE, Hussain M, Bianco FJ, Jr., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440–2447.

    CAS  PubMed  Google Scholar 

  89. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218–2224.

    CAS  PubMed  Google Scholar 

  90. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 2005;103:2298–2303.

    CAS  PubMed  Google Scholar 

  91. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527–2533.

    CAS  PubMed  Google Scholar 

  92. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–3181.

    CAS  PubMed  Google Scholar 

  93. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.

    CAS  PubMed  Google Scholar 

  94. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25:abstract 4000.

    Google Scholar 

  95. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–2048.

    CAS  PubMed  Google Scholar 

  96. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–578.

    CAS  PubMed  Google Scholar 

  97. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Journal of Clinical Oncology 2004;22:abstract 5502.

    Google Scholar 

  98. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171–2177.

    CAS  PubMed  Google Scholar 

  99. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized phase III (Extreme) study. Journal of Clinical Oncology 2007;25:abstract 6091.

    Google Scholar 

  100. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201–1208.

    CAS  PubMed  Google Scholar 

  101. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71.

    CAS  PubMed  Google Scholar 

  102. Goddard JC, Sutton CD, Furness PN, O'Byrne KJ, Kockelbergh RC. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003;9:2583–2586.

    PubMed  Google Scholar 

  103. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36:401–405.

    PubMed  Google Scholar 

  104. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.

    CAS  PubMed  Google Scholar 

  105. Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22:1–6.

    PubMed  Google Scholar 

  106. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001;8:9–15.

    CAS  PubMed  Google Scholar 

  107. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:1190–1194.

    CAS  PubMed  Google Scholar 

  108. Li N, Kanda K, Fukumori T, et al. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer. Urol Oncol 2000;6:10–15.

    PubMed  Google Scholar 

  109. Li S, Nomata K, Sawase K, Noguchi M, Kanda S, Kanetake H. Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. Int J Urol 2001;8:478–482.

    CAS  PubMed  Google Scholar 

  110. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006;295:2516–2524.

    CAS  PubMed  Google Scholar 

  111. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16–24.

    CAS  PubMed  Google Scholar 

  112. Demetri G, van Oosterom T, Blackstein M, et al. Phase 3, mulitcenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005:Abstract 4000.

    Google Scholar 

  113. Ratain M, Eisen T, Stadler W, et al. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005:abstract 4544.

    Google Scholar 

  114. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–2512.

    CAS  PubMed  Google Scholar 

  115. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2005:abstract 4510.

    Google Scholar 

  116. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.

    CAS  PubMed  Google Scholar 

  117. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645–4655.

    CAS  PubMed  Google Scholar 

  118. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284–7290.

    CAS  PubMed  Google Scholar 

  119. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546–1556.

    CAS  PubMed  Google Scholar 

  120. Natale RBD, Govindan R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: results of a randomized, double-blind Phase II study. Lung Cancer 2005;49:S37.

    Google Scholar 

  121. Herbst RJB, Rowbottom J et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized placebo-controlled Phase II trial. Lung Cancer 2005;49:S35.

    Google Scholar 

  122. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62–66.

    CAS  PubMed  Google Scholar 

  123. Arts J, de Schepper S, Van Emelen K. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 2003;10:2343–2350.

    CAS  PubMed  Google Scholar 

  124. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495–528.

    CAS  PubMed  Google Scholar 

  125. Canes D, Chiang GJ, Billmeyer BR, et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 2005;113:841–848.

    CAS  PubMed  Google Scholar 

  126. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578–3588.

    CAS  PubMed  Google Scholar 

  127. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:2876–2881.

    CAS  PubMed  Google Scholar 

  128. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.

    CAS  PubMed  Google Scholar 

  129. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004;91:844–849.

    CAS  PubMed  Google Scholar 

  130. Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998;16:1844–1848.

    CAS  PubMed  Google Scholar 

  131. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002;95:1022–1027.

    CAS  PubMed  Google Scholar 

  132. Johannsen M, Sachs M, Roigas J, et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur Urol 2005;48:246–251.

    CAS  PubMed  Google Scholar 

  133. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000;18:1058–1061.

    CAS  PubMed  Google Scholar 

  134. Burch PA, Richardson RL, Cha SS, et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 2000;164:1538–1542.

    CAS  PubMed  Google Scholar 

  135. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999;10:1385–1388.

    CAS  PubMed  Google Scholar 

  136. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002;86:326–330.

    CAS  PubMed  Google Scholar 

  137. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004;22:393–397.

    CAS  PubMed  Google Scholar 

  138. Theodore C, Bidault F, Bouvet-Forteau N, et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 2006;17:990–994.

    CAS  PubMed  Google Scholar 

  139. Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000;88:1671–1678.

    CAS  PubMed  Google Scholar 

  140. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Gandour-Edwards R, deVere White RW. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000;55:521–525.

    CAS  PubMed  Google Scholar 

  141. Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005;92:645–650.

    CAS  PubMed  Google Scholar 

  142. Tsavaris N, Kosmas C, Skopelitis H, et al. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study. J Chemother 2005;17:441–448.

    CAS  PubMed  Google Scholar 

  143. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–1264.

    CAS  PubMed  Google Scholar 

  144. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365–370.

    CAS  PubMed  Google Scholar 

  145. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384–1390.

    CAS  PubMed  Google Scholar 

  146. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217–1221.

    CAS  PubMed  Google Scholar 

  147. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007–1013.

    CAS  PubMed  Google Scholar 

  148. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000;164:1177–1182.

    CAS  PubMed  Google Scholar 

  149. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38:691–699;discussion 700.

    CAS  PubMed  Google Scholar 

  150. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090–1094.

    CAS  PubMed  Google Scholar 

  151. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251–1256.

    CAS  PubMed  Google Scholar 

  152. Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004;24:1011–1023.

    CAS  PubMed  Google Scholar 

  153. Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256–1261.

    CAS  PubMed  Google Scholar 

  154. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919–925.

    CAS  PubMed  Google Scholar 

  155. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120–1125.

    CAS  PubMed  Google Scholar 

  156. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25:9–17.

    CAS  PubMed  Google Scholar 

  157. Miyamoto H, Kubota Y, Noguchi S, et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000;55:679–683.

    CAS  PubMed  Google Scholar 

  158. Hussain M, Trastuzumab T, Paclitaxel P, Carboplatin C, and Gemcitabine G in Advanced HER2-positive Urothelial Carcinoma: Results of a Multi-Center Phase II NCI Trial. Proc Am Soc Clin Oncol 2005;23:abstract 4507.

    Google Scholar 

  159. Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493–2498.

    CAS  PubMed  Google Scholar 

  160. Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6:4866–4873.

    CAS  PubMed  Google Scholar 

  161. Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001;92:188–193.

    CAS  PubMed  Google Scholar 

  162. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072–1079.

    CAS  PubMed  Google Scholar 

  163. Migaldi M, Sgambato A, Garagnani L, et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131–3138.

    CAS  PubMed  Google Scholar 

  164. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000;31:751–760.

    CAS  PubMed  Google Scholar 

  165. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84:1242–1251.

    CAS  PubMed  Google Scholar 

  166. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129–1136.

    PubMed  Google Scholar 

  167. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241–3245.

    CAS  PubMed  Google Scholar 

  168. Otto T, Birchmeier W, Schmidt U, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 1994;54:3120–3123.

    CAS  PubMed  Google Scholar 

  169. Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 1995;121:303–308.

    CAS  PubMed  Google Scholar 

  170. Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998;160:1889–1893.

    CAS  PubMed  Google Scholar 

  171. Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165:1473–1479.

    CAS  PubMed  Google Scholar 

  172. Miyake H, Eto H, Arakawa S, Kamidono S, Hara I. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002;167:1282–1287.

    PubMed  Google Scholar 

  173. Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996;47:34–37.

    CAS  PubMed  Google Scholar 

  174. Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 2003;61:1053–1058.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA

    Deborah Bradley

  2. Department of Radiology, University of Michigan, Ann Arbor, MI, USA

    Maha Hussain

Authors
  1. Deborah Bradley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maha Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maha Hussain .

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bradley, D., Hussain, M. (2009). Beyond MVAC: New and Improved Chemotherapeutics. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_24

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation